US › Healthcare

Invivyd Inc. (IVVD)

US · Healthcare · Biotechnology

$0.75-7.34%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$14.3M

Revenue YoY

+21.2%

Net profit

$-44.4M

EPS

$-0.14

EPS estimate

$-0.15

Net margin

-310.8%

EPS came in at -0.14 against a street estimate of -0.15 — a beat of 6.7%.

Key statistics

Market cap

$231.5M

Forward P/E

44.6

P/B

1.26

Book value

$0.61

EPS (TTM)

$-0.31

52-week high

$3.07

52-week low

$0.53

50-day MA

$0.77

200-day MA

$1.47

Beta

0.81

Analyst view

Analysts rate Invivyd Inc. a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $10.00.

Shareholding

Insiders

7.16%

Institutions

86.84%

Largest institutional holders

Fund	Stake
HHG PLC	11.23%
Perceptive Advisors LLC	7.08%
Bvf Inc	6.62%
Maverick Capital Ltd	6.44%
Vanguard Capital Management, LLC	3.42%
M28 Capital Management LP	3.14%
Driehaus Capital Management LLC	2.86%
Saturn V Capital Management LLC	2.85%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Invivyd Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.